Go to the list of all blogs
Allana's Avatar
published in Blogs
Sep 03, 2026
TickeronGET DAILY SIGNALS
Why Is Phreesia (PHR) Stock Down -8.27% Today?

Why Is Phreesia (PHR) Stock Down -8.27% Today?

Key Takeaways

  • Phreesia (PHR) shares fell about 8.27% to $10.87 after reporting mixed fiscal second-quarter results.
  • The primary catalyst was an earnings miss: adjusted EPS of $0.03 came in well below the $0.09 consensus estimate.
  • Revenue of roughly $129.5 million narrowly beat expectations and rose 10% year over year, but the profit shortfall overshadowed the top-line beat.
  • Management maintained its fiscal 2027 revenue and adjusted EBITDA outlook, cushioning the decline but not preventing it.
  • Analyst reactions were mixed, with some firms reiterating bullish ratings while Wells Fargo kept a cautious Equal Weight stance.
  • Traders are now watching guidance execution, subscription revenue trends, and momentum in the company's Network Solutions segment.

Opening Summary

Phreesia, Inc. (PHR), a healthcare technology company that provides patient intake and engagement software to medical practices, saw its shares plunge in Thursday's session after a quarterly earnings miss. The stock fell approximately 8.27% to $10.87, down from a prior closing price of $11.85. The market reaction was driven by adjusted earnings that came in sharply below Wall Street expectations, even as revenue topped forecasts and the company reaffirmed its full-year outlook.

Earnings Miss Weighs on Shares

The dominant driver of the decline was Phreesia's fiscal 2027 second-quarter earnings report, released after the prior session's close. The company posted adjusted earnings per share of $0.03, missing the consensus estimate of approximately $0.09 by a wide margin. Although net income improved from the year-ago period, the magnitude of the profit shortfall relative to analyst models triggered a swift sell-off, with shares gapping down at the open.

The earnings-driven move underscores how sensitive small- and mid-cap healthcare software names can be to bottom-line results, particularly when investors have priced in a continued profitability ramp. Despite the miss, the company emphasized its fifth consecutive quarter of positive net income and its ninth consecutive quarter of positive operating and free cash flow.

Revenue Beat and Maintained Guidance Provide Partial Offset

Not all of the quarter's metrics were negative. Phreesia reported revenue of approximately $129.5 million, slightly ahead of the $129.1 million consensus and up about 10% year over year. Growth was supported by an expanding client base and momentum in the company's Network Solutions business.

Management also reaffirmed its fiscal 2027 revenue guidance of $510 million to $520 million and its adjusted EBITDA outlook of $125 million to $135 million, a move that reduced the risk of a near-term guidance cut. The company highlighted the AccessOne patient-financing acquisition as a multi-year growth opportunity and noted that it reduced debt principal by more than $23 million during the quarter, supporting an improving balance sheet. These positives helped limit losses but were not enough to offset the headline earnings miss.

Analyst Reaction Remains Mixed

The post-earnings analyst response reflected a divided view on the stock's path forward. Wells Fargo raised its price target to $10 from $9 while maintaining an Equal Weight rating, pointing to solid Network segment growth and better-than-expected adjusted EBITDA margins, but flagging continued pressure on subscription revenue. Needham reiterated a Buy rating with a $14 target, and RBC Capital maintained an Outperform rating with a $19 target, while DA Davidson reiterated a Buy at $14.

The mixed revisions signal that, while the long-term thesis around Phreesia's platform and patient-financing expansion remains intact for some analysts, near-term concerns about subscription revenue dilution and limited visibility in newer segments continue to weigh on sentiment.

Market Context and Trading Activity

Trading volume in Phreesia shares was elevated relative to recent sessions as investors repositioned following the earnings release. The stock's decline was largely company-specific rather than a reflection of broader market direction, with the move driven primarily by the earnings disappointment and a gap-down open.

The decline also brought the stock back toward key technical levels, with the share price retreating toward its 50-day moving average after recently trading above the $12 level. The gap down reflects a pronounced negative market reaction rather than a gradual drift, consistent with an earnings-driven repricing event.

What Comes Next for PHR

Investors will be closely monitoring several factors in the weeks ahead. Attention will focus on whether Phreesia can sustain its revenue growth trajectory while protecting subscription economics, given management's strategy of moderating pricing to support providers under economic strain. The company's Network Solutions segment, including the ProviderConnect pilot and its GLP-1 campaign results, will be watched as a potential growth catalyst.

Upcoming earnings, broader healthcare technology sector trends, and any further analyst rating changes could also influence the stock's direction. Risks include continued subscription revenue pressure, competitive dynamics from electronic health record vendors, and execution uncertainty around newer initiatives such as AccessOne. As always, near-term volatility around earnings should be expected.

Trending AI Robots

For investors seeking a more systematic approach to the markets, Tickeron's Trending AI Robots page highlights AI-driven trading bots that are currently performing strongly. Tickeron offers hundreds of AI trading bots covering thousands of tickers, but only the strongest performers under current market conditions are featured in this curated section. These bots vary by strategy, timeframe, performance metrics, and traded symbols, allowing users to explore approaches that fit different investing styles. Explore the Trending AI Robots page to see which automated strategies are leading right now.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: PHR

Contributor

Allana's AvatarAllana|Expert

Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.


Momentum Indicator for PHR turns negative, indicating new downward trend

PHR saw its Momentum Indicator move below the 0 level on November 18, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned negative. In 73 of the 88 cases, the stock moved further down in the following days. The odds of a decline are at 83%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The 10-day RSI Indicator for PHR moved out of overbought territory on November 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 similar instances where the indicator moved out of overbought territory. In 19 of the 27 cases, the stock moved lower in the following days. This puts the odds of a move lower at 70%.

The Moving Average Convergence Divergence Histogram (MACD) for PHR turned negative on November 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In 41 of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where PHR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.

Bullish Trend Analysis

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

PHR moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for PHR crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 90%.

The 50-day moving average for PHR moved above the 200-day moving average on October 27, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +1.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where PHR advanced for three days, in 218 of 296 cases, the price rose further within the following month. The odds of a continued upward trend are 74%.

PHR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 110 of 132 cases where PHR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 83%.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 53 (best 1 - 100 worst), indicating steady price growth. PHR’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.107) is normal, around the industry mean (4.523). PHR has a moderately high P/E Ratio (70.111) as compared to the industry average of (12.601). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (1.270) is also within normal values, averaging (6.105).

The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PHR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 98, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teladoc Health (NYSE:TDOC).

Industry description

This industry comprises companies that provide services, such as equipment sterilization, research, physician management systems and consulting, that support the healthcare/medical industry. Examples of such companies include Laboratory Corporation of America Holdings, which operates one of the largest clinical laboratory networks in the world; Quest Diagnostics Inc., which is a clinical laboratory; and Syneos Health, which is a major clinical research organization.

Market Cap

The average market capitalization across the Services to the Health Industry Industry is 3.31B. The market cap for tickers in the group ranges from 708 to 49.18B. VEEV holds the highest valuation in this group at 49.18B. The lowest valued company is OTRKQ at 708.

High and low price notable news

The average weekly price growth across all stocks in the Services to the Health Industry Industry was -13%. For the same Industry, the average monthly price growth was -13%, and the average quarterly price growth was 2%. DRIO experienced the highest price growth at 5%, while LFMD experienced the biggest fall at -34%.

Volume

The average weekly volume growth across all stocks in the Services to the Health Industry Industry was 27%. For the same stocks of the Industry, the average monthly volume growth was 34% and the average quarterly volume growth was -7%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 53
Price Growth Rating: 58
SMR Rating: 86
Profit Risk Rating: 97
Seasonality Score: -5 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a provider of patient check-in solutions for medical practices

Industry ServicestotheHealthIndustry

Industry
N/A
Address
1521 Concord Pike
Phone
+1 888 654-7473
Employees
1789
Web
https://www.phreesia.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.